Skip to main content
Fri, Mar 20, 2026
TrendingNews.today
World News
S&P 500 5,142.30 ▲ +0.87%|NASDAQ 16,284.75 ▲ +1.12%|DOW 38,972.10 ▼ -0.23%|AAPL $192.45 ▲ +1.80%|TSLA $241.80 ▼ -2.10%|AMZN $178.92 ▲ +0.54%|GOOGL $141.20 ▲ +0.32%|MSFT $415.60 ▼ -0.15%|
S&P 500 5,142.30 ▲ +0.87%|NASDAQ 16,284.75 ▲ +1.12%|DOW 38,972.10 ▼ -0.23%|AAPL $192.45 ▲ +1.80%|TSLA $241.80 ▼ -2.10%|AMZN $178.92 ▲ +0.54%|GOOGL $141.20 ▲ +0.32%|MSFT $415.60 ▼ -0.15%|
HealthUnited States1 sourcesNeutral

Kalohexis Emerges from Stealth to Advance First- and Best-in-Class Therapeutics Harnessing the Melanocortin System to Treat Obesity and Metabolic Diseases

Kalohexis' lead programs include 710GO, an oral dual melanocortin-3 and-4 receptor (MC3R/MC4R) agonist, a next-generation general obesity treatment; and mifomelatide, a dual MC3R/MC4R antagonist to prevent and treat cachexia in advanced cancers 710GO has shown healthier, more durable...

CP
cision pr newswire
via Pr Newswire
ShareRead original

Read the full article at Pr Newswire →

Kalohexis Emerges from Stealth to Advance First- and Best-in-Class Therapeutics Harnessing the Melanocortin System to Treat Obesity and Metabolic Diseases

Source Verification

Corroboration Score: 1

This story was independently reported by 1 sources. Click any source to read the original article.

Pr Newswire
Pr Newswire
NewsDataUS

Comments

0 comments
Be respectful and constructive.
Loading comments...
Previous
Topology Helps Build More Robust Photonic Networks - University of Pennsylvania
Next
Uber, Rivian announce $1.25 billion deal for 50,000 robotaxis

Related Articles

Malaysia Bourse May Test Support At 1,700 PointsHealth
Malaysia Bourse May Test Support At 1,700 Points
Unknown-2h ago-2 sources
Soft Start Anticipated For South Korea SharesHealth
Soft Start Anticipated For South Korea Shares
Unknown-3h ago-2 sources
Treasuries Close Lower After Recovery Attempt FaltersHealth
Treasuries Close Lower After Recovery Attempt Falters
Unknown-6h ago-1 sources